BIOFLUIDICA

Company Overview

BioFluidica Inc., founded in 2006 as a spin-out from Louisiana State University, is developing and commercializing CTC detection and analysis platforms. BioFluidica’s main approach is to offer an integrated cell capture and analysis system on a single cartridge form factor.

BioFluidica has developed a CTC capture platform, consisting of a plastic cartridge that contains a capture bed with antibody-coated channels. The antibodies are chemically bound to the surface of the capture bed. The antibodies are attached to the surface using single-stranded DNA linkers. The captured CTCs are released by enzymatically cleaving the DNA linker. Once released, the CTCs can be counted using electrical conductivity.

This capture method compares very favorably with the CellSearch platform, with approximately two orders of magnitude higher capture of CTCs across multiple cancers.

The company’s Liquid Scan platform examines blood samples for CTCs, cfDNA and/or exosomes. It is analogous to a CT or MRI scan, which examines the whole body for the presence of disease.

In July 2023, company launched its Prenatal Blood Screening study by taking out fetal cells from a simple blood draw, providing valuable insights into the baby’s genetic composition.

Company's Business Segments

• Liquid Biopsy : This segment offers various liquid biopsy platforms, scientific instruments, software systems, and reagents designed to provide better values for clinicians, scientists, and patients.